TABLE 3

Dose recommendations based on the results from this study compared with the WHO revised dosagesa

DrugTarget (value)Wt band (kg)NAT2 genotypeDose achieving 90% TAWHO revised dosage (mg) in:
mgmg/kg20102014
RifampinCmax (3.01 μg/ml)5–712018.612060–120
8–1418014.4180120–180
15–2024013.6300240–300
21–3024010.7420300
AUC0–24 (3.70 mg · h/liter)5–7609.312060–120
8–14604.8180120–180
15–201206.8300240–300
21–301205.4420300
IsoniazidCmax (3 μg/ml)5–7All609.39030–60
8–14All907.212060–90
15–20All1206.8210120–150
21–30All2109.4270150
AUC0–24 (11.95 mg · h/liter)5–7Nonslow12018.59030–60
8–14Nonslow21017.112060–90
15–20Nonslow27014.8210120–150
21–30Nonslow27012.2270150
5–7Slow609.49030–60
8–14Slow907.212060–90
15–20Slow1206.9210120–150
21–30Slow2108.7270150
PyrazinamideCmax (20 μg/ml)5–730046.5150150–300
8–1445036.0300300–450
15–2045025.4450600–750
21–3060026.8800750
Cmax (38.1 μg/ml)5–745069.8150150–300
8–1480064.0300300–450
15–2090050.8450600–750
21–301,05046.9800750
EthambutolCmax (2 μg/ml)5–740062.0100100–200
8–1455044.0200200
15–2055031.1300300–400
21–3055024.6550400
  • a NAT2, N-acetyltransferase 2 gene; TA, target attainment.